Skip to main content

Table 1 Licensed biologics for severe asthma

From: Biological therapy for severe asthma

DRUG NAME TARGET MODE OF ADMINISTRATION CRITERIA OF PRESCRIPTION AGE INDICATION DOSING INTERVAL DOSAGE
Omalizumab IgE Subcutaneous injection high blood IgE; sensititazion to perennial allergen ≥6 years 14 days or 28 days 75 mg to 600 mg (based on kg and tot IgE)
Mepolizumab IL-5 Subcutaneous injection high blood eosinophils ≥6 years 28 days 100 mg
Reslizumab IL-5 Intravenous injection high blood eosinophils ≥ 18 years 28 days 3 mg/kg
Benralizumab IL-5 receptor a Subcutaneous injection high blood eosinophils ≥ 18 years 28 days (56 days after 3 months) 30 mg
Dupilumab IL-4 receptor alpha Subcutaneous injection high blood eosinophils and/or raised FeNO ≥12 years 14 days 200 mg to 300 mg (based on comorbidities)